Unknown

Dataset Information

0

Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.


ABSTRACT: Formation of the androgen receptor splicing variant 7 (AR-V7) is one of the major mechanisms by which resistance of prostate cancer to androgen deprivation therapy occurs. The histone demethylase JMJD1A (Jumonji domain containing 1A) functions as a key coactivator for AR by epigenetic regulation of H3K9 methylation marks. Here, we describe a role for JMJD1A in AR-V7 expression. While JMJD1A knockdown had no effect on full-length AR (AR-FL), it reduced AR-V7 levels in prostate cancer cells. Reexpression of AR-V7 in the JMJD1A-knockdown cells elevated expression of select AR targets and partially rescued prostate cancer cell growth in vitro and in vivo. The AR-V7 protein level correlated positively with JMJD1A in a subset of human prostate cancer specimens. Mechanistically, we found that JMJD1A promoted alternative splicing of AR-V7 through heterogeneous nuclear ribonucleoprotein F (HNRNPF), a splicing factor known to regulate exon inclusion. Knockdown of JMJD1A or HNRNPF inhibited splicing of AR-V7, but not AR-FL, in a minigene reporter assay. JMJD1A was found to interact with and promote the recruitment of HNRNPF to a cryptic exon 3b on AR pre-mRNA for the generation of AR-V7. Taken together, the role of JMJD1A in AR-FL coactivation and AR-V7 alternative splicing highlights JMJD1A as a potentially promising target for prostate cancer therapy.

SUBMITTER: Fan L 

PROVIDER: S-EPMC5960326 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.

Fan Lingling L   Zhang Fengbo F   Xu Songhui S   Cui Xiaolu X   Hussain Arif A   Fazli Ladan L   Gleave Martin M   Dong Xuesen X   Qi Jianfei J  

Proceedings of the National Academy of Sciences of the United States of America 20180430 20


Formation of the androgen receptor splicing variant 7 (AR-V7) is one of the major mechanisms by which resistance of prostate cancer to androgen deprivation therapy occurs. The histone demethylase JMJD1A (Jumonji domain containing 1A) functions as a key coactivator for AR by epigenetic regulation of H3K9 methylation marks. Here, we describe a role for JMJD1A in AR-V7 expression. While JMJD1A knockdown had no effect on full-length AR (AR-FL), it reduced AR-V7 levels in prostate cancer cells. Reexp  ...[more]

Similar Datasets

| S-EPMC7809134 | biostudies-literature
| S-EPMC7113292 | biostudies-literature
| S-EPMC7581977 | biostudies-literature
| S-EPMC5644285 | biostudies-literature
| S-EPMC6995728 | biostudies-literature
| S-EPMC6036217 | biostudies-literature
2021-01-21 | GSE143907 | GEO
| S-EPMC10093438 | biostudies-literature
| S-EPMC8214144 | biostudies-literature
2021-07-07 | GSE143906 | GEO